A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
Abstract Background Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease with different subtypes, multidisciplinary teams-led management, and a poor prognosis. Currently, the clinical benefits of stage III NSCLC in the neoadjuvant setting are still unclear. We performed a meta-ana...
Hauptverfasser: | , , , , |
---|---|
Format: | Artikel |
Sprache: | English |
Veröffentlicht: |
BMC
2022-12-01
|
Schriftenreihe: | BMC Pulmonary Medicine |
Schlagworte: | |
Online Zugang: | https://doi.org/10.1186/s12890-022-02292-5 |